Hybio Pharmaceutical (300199.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE1000011T7
Hybio Pharmaceutical financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 590.20 m CNY | 966.35 m CNY |
| Gross profit | 308.73 m CNY | 564.00 m CNY |
| Operating income | -161.39 m CNY | 218.53 m CNY |
| EBIT | -32.41 m CNY | 162.27 m CNY |
| Net income | -173.65 m CNY | 36.57 m CNY |
| Diluted EPS – continuing operations | -0.20 CNY | 0.04 CNY |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as medical devices comprising disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; mental and behavioral disorders; tumor; urogenital system diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services, technical services, technology development, technical consulting, technical exchange, technology transfer, and technology promotion, as well as non-residential real estate leasing. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.
More stocks
- CarGurus, Inc. (CARG)
- Guangshen Railway Co Ltd (601333.SS)
- JHT Design Co. Ltd. Cl A (603061.SS)
- Topaz Energy Corp (TPZ.TO)
- Hangzhou EZVIZ Network Co. Ltd. A (688475.SS)
- Indosat Tbk (ISAT.JK)
- Amplifon SpA (AMP.MI)
- Sparebank 1 Sorost-Norge (SOON.OL)
- Shanghai Sinyang Semiconductor (300236.SZ)
- Guangdong HongDa Blasting Co Ltd (002683.SZ)
- Compass Gas e Energia SA (PASS3.SA)
- Carel Industries SpA (CRL.MI)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.